Frontiers in medicine · 2026
Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: an umbrella review of meta-analyses on liver enzymes.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khurmatullina Alsu R, Andreev Dmitrii N, Maev Igor V, Zaborovsky Andrey V, Kucheryavyy Yury A, Beliy Petr A, Sokolov Philipp S
Аннотация
OBJECTIVE: This umbrella review aimed to systematically synthesize and evaluate evidence from published meta-analyses regarding the efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease, focusing on its impact on liver-specific biochemical markers.
METHODS: Following Joanna Briggs Institute methodology and registered in PROSPERO (ID: CRD420251250211), a comprehensive search of MEDLINE, EMBASE, Cochrane Library, and Scopus (1985-2025) identified systematic reviews and meta-analyses evaluating UDCA therapy in MASLD. Methodological quality was appraised using AMSTAR-2, ROBIS, and GRADE frameworks. Data on hepatic biomarkers were extracted and synthesized using fixed- or random-effects models depending on heterogeneity (I2 statistic). Overlap among primary studies was assessed using the GROOVE tool, and meta-regression explored the influence of treatment duration on ALT dynamics.
RESULTS: Five meta-analyses (33 primary studies; 5,015 participants) were eligible. UDCA demonstrated consistent and statistically significant improvements in key markers of hepatocellular injury, including ALT (SMD = -0.36; 95% CI: -0.69 to -0.03) and AST (SMD = -0.16; 95% CI: -0.22 to -0.10), as well as cholestatic markers such as GGT (SMD = -0.40; 95% CI: -0.63 to -0.18) and ALP (SMD = -0.23; 95% CI: -0.31 to -0.14), total bilirubin decreased modestly (SMD = -0.08; 95% CI: -0.15 to -0.01), while albumin level remained unchanged. Meta-regression showed that longer treatment duration was significantly associated with greater ALT reduction (-0.04 SMD per 6 months; p = 0.034).
CONCLUSION: UDCA demonstrates consistent hepatoprotective and cholestasis-modifying effects in MASLD. Longer treatment duration may enhance biochemical responses.
SYSTEMATIC REVIEW REGISTRATION: CRD420251250211.
METHODS: Following Joanna Briggs Institute methodology and registered in PROSPERO (ID: CRD420251250211), a comprehensive search of MEDLINE, EMBASE, Cochrane Library, and Scopus (1985-2025) identified systematic reviews and meta-analyses evaluating UDCA therapy in MASLD. Methodological quality was appraised using AMSTAR-2, ROBIS, and GRADE frameworks. Data on hepatic biomarkers were extracted and synthesized using fixed- or random-effects models depending on heterogeneity (I2 statistic). Overlap among primary studies was assessed using the GROOVE tool, and meta-regression explored the influence of treatment duration on ALT dynamics.
RESULTS: Five meta-analyses (33 primary studies; 5,015 participants) were eligible. UDCA demonstrated consistent and statistically significant improvements in key markers of hepatocellular injury, including ALT (SMD = -0.36; 95% CI: -0.69 to -0.03) and AST (SMD = -0.16; 95% CI: -0.22 to -0.10), as well as cholestatic markers such as GGT (SMD = -0.40; 95% CI: -0.63 to -0.18) and ALP (SMD = -0.23; 95% CI: -0.31 to -0.14), total bilirubin decreased modestly (SMD = -0.08; 95% CI: -0.15 to -0.01), while albumin level remained unchanged. Meta-regression showed that longer treatment duration was significantly associated with greater ALT reduction (-0.04 SMD per 6 months; p = 0.034).
CONCLUSION: UDCA demonstrates consistent hepatoprotective and cholestasis-modifying effects in MASLD. Longer treatment duration may enhance biochemical responses.
SYSTEMATIC REVIEW REGISTRATION: CRD420251250211.